Top

Published in:

Open Access 01-12-2011 | Research

Prognostic Significance of Wnt-1, β-catenin and E-cadherin Expression in Advanced Colorectal Carcinoma

Authors: Aleksandra Stanczak, Rafal Stec, Lubomir Bodnar, Wojciech Olszewski, Marzena Cichowicz, Wojciech Kozlowski, Cezary Szczylik, Tadeusz Pietrucha, Maciej Wieczorek, Monika Lamparska-Przybysz

Published in: Pathology & Oncology Research | Issue 4/2011

Abstract

Wnt/β-catenin pathway plays an important role in initiation and progression of colorectal oncogenesis. The aim of this study was to determine expression and localization of E-cadherin, β-catenin and Wnt-1 proteins in colorectal tumors. Expression of β-catenin, E-cadherin and Wnt-1 was determined by immunohistochemistry on advanced colorectal cancers. Abnormal expression of E-cadherin, β-catenin, Wnt-1 was observed. Additionally, we revealed correlations between levels of studied proteins and histoclinical data. In multivariate analysis nuclear β-catenin, higher carcinoembryonic antigen serum level before treatment, female sex and tumor localized in colon or rectum were independent unfavorable prognostic factors. These findings support the hypothesis that Wnt/β-catenin pathway plays an important role in advanced colorectal carcinoma.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr. Cited 20 Sept 2010

Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R (2009) EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 45:931–91PubMedCrossRef

American Joint Committee on Cancer (2010) Colon and rectum. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC Cancer Staging Manual, The Seventh Edition. Springer, New York

Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR et al (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979–94PubMed

Chen JS, Hsieh PS, Chiang JM, Yeh CY, Tsai WS, Tang R et al (2010) Clinical outcome of signet ring cell carcinoma and mucinous adenocarcinoma of the colon. Chang Gung Med J 33:51–7PubMed

Matsumoto K, Nakayama Y, Inoue Y, Minagawa N, Katsuki T, Shibao K et al (2007) Lymphatic microvessel density is an independent prognostic factor in colorectal cancer. Dis Colon Rectum 50:308–14PubMedCrossRef

MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17:9–26PubMedCrossRef

Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–6PubMedCrossRef

Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T (1999) beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155:1033–8PubMedCrossRef

10.

He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509–12PubMedCrossRef

11.

Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ et al (2001) Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61:8664–7PubMed

12.

Gavert N, Ben-Ze’ev A (2007) beta-Catenin signaling in biological control and cancer. J Cell Biochem 102:820–8PubMedCrossRef

13.

Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN et al (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359:235–7PubMedCrossRef

14.

Sparks AB, Morin PJ, Vogelstein B, Kinzler KW (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130–4PubMed

15.

Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787–90PubMedCrossRef

16.

Hugh TJ, Dillon SA, O’Dowd G, Getty B, Pignatelli M, Poston GJ et al (1999) beta-catenin expression in primary and metastatic colorectal carcinoma. Int J Cancer 82:504–11PubMedCrossRef

17.

Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR (1999) Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 80:1046–51PubMedCrossRef

18.

Han SA, Chun H, Park CM, Kang SJ, Kim SH, Sohn D et al (2006) Prognostic significance of beta-catenin in colorectal cancer with liver metastasis. Clin Oncol (R Coll Radiol) 18:761–7CrossRef

19.

Krzakowski M (ed) (2001) Onkologia kliniczna, 1st edn. Warsaw, Borgis Wydawnictwo Medyczne

20.

Delektorskaya VV, Perevoshchikov AG, Golovkov DA, Kushlinskii NE (2005) Expression of E-cadherin, beta-catenin, and CD-44v6 cell adhesion molecules in primary tumors and metastases of colorectal adenocarcinoma. Bull Exp Biol Med 139:706–10PubMedCrossRef

21.

Choi HN, Kim KR, Lee JH, Park HS, Jang KY, Chung MJ et al (2009) Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex. Oncol Rep 21:57–63PubMed

22.

Filiz AI, Senol Z, Sucullu I, Kurt Y, Demirbas S, Levhi Akin M (2010) The survival effect of E-cadherin and catenins in colorectal carcinomas. Colorectal Dis 12:1223–30PubMedCrossRef

23.

El-Bahrawy MA, Poulsom R, Jeffery R, Talbot I, Alison MR (2001) The expression of E-cadherin and catenins in sporadic colorectal carcinoma. Hum Pathol 32:1216–24PubMedCrossRef

24.

Schuhmacher C, Becker I, Oswald S, Atkinson MJ, Nekarda H, Becker KF et al (1999) Loss of immunohistochemical E-cadherin expression in colon cancer is not due to structural gene alterations. Virchows Arch 434:489–95PubMedCrossRef

25.

Hahn-Strömberg V, Edvardsson H, Bodin L, Franzén L (2008) Disturbed expression of E-cadherin, beta-catenin and tight junction proteins in colon carcinoma is unrelated to growth pattern and genetic polymorphisms. APMIS 116:253–62PubMedCrossRef

26.

Huiping C, Sigurgeirsdottir JR, Jonasson JG, Eiriksdottir G, Johannsdottir JT, Egilsson V et al (1999) Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer 81:1103–10PubMedCrossRef

27.

Huiping C, Kristjansdottir S, Jonasson JG, Magnusson J, Egilsson V, Ingvarsson S (2001) Alterations of E-cadherin and beta-catenin in gastric cancer. BMC Cancer 1:16PubMedCrossRef

28.

Truant SC, Gouyer VP, Leteurtre EA, Zerimech F, Huet GM, Pruvot FR (2008) E-cadherin and beta-catenin mRNA levels throughout colon cancer progression. J Surg Res 150:212–8PubMedCrossRef

29.

Avizienyte E, Wyke AW, Jones RJ, McLean GW, Westhoff MA, Brunton VG et al (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 4:632–8PubMed

30.

Ikeguchi M, Makino M, Kaibara N (2001) Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. J Surg Oncol 77:201–7PubMedCrossRef

31.

Miyamoto S, Endoh Y, Hasebe T, Ishii G, Kodama K, Goya M et al (2004) Nuclear beta-catenin accumulation as a prognostic factor in Dukes’ D human colorectal cancers. Oncol Rep 12:245–51PubMed

32.

Elzagheid A, Buhmeida A, Korkeila E, Collan Y, Syrjanen K, Pyrhonen S (2008) Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol 14:3866–71PubMedCrossRef

33.

Vider BZ, Zimber A, Chastre E, Prevot S, Gespach C, Estlein D et al (1996) Evidence for the involvement of the Wnt 2 gene in human colorectal cancer. Oncogene 12:153–8PubMed

34.

Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, Truong T (2002) Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 55:220–6PubMedCrossRef

35.

Khor TO, Gul YA, Ithnin H, Seow HF (2006) A comparative study of the expression of Wnt-1, WISP-1, survivin and cyclin-D1 in colorectal carcinoma. Int J Colorectal Dis 21:291–300PubMedCrossRef

36.

Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A et al (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253:665–669PubMedCrossRef

37.

Nakamura Y, Nishisho I, Kinzler KW, Vogelstein B, Miyoshi Y, Miki Y et al (1992) Mutations of the APC (adenomatous polyposis coli) gene in FAP (familial polyposis coli) patients and in sporadic colorectal tumors. Tohoku J Exp Med 168:141–7PubMedCrossRef

38.

Varesco L, Gismondi V, James R, Robertson M, Grammatico P, Groden J et al (1993) Identification of APC gene mutations in Italian adenomatous polyposis coli patients by PCR-SSCP analysis. Am J Hum Genet 52:280–5PubMed

39.

Polakis P, Hart M, Rubinfeld B (1999) Defects in the regulation of beta-catenin in colorectal cancer. Adv Exp Med Biol 470:23–32PubMedCrossRef

40.

Joo M, Shahsafaei A, Odze RD (2009) Paneth cell differentiation in colonic epithelial neoplasms: evidence for the role of the Apc/beta-catenin/Tcf pathway. Hum Pathol 40:872–80PubMedCrossRef

41.

Chiang JM, Chou YH, Chen TC, Ng KF, Lin JL (2002) Nuclear beta-catenin expression is closely related to ulcerative growth of colorectal carcinoma. Br J Cancer 86:1124–9PubMedCrossRef

42.

Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA et al (2001) Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 195:171–8PubMedCrossRef

43.

Aamodt R, Bondi J, Andersen SN, Bukholm G, Bukholm IRK (2008) Expression of nuclear β-Catenin in rectal versus colonic cancers. Open Clin Cancer J 2:13–17CrossRef

44.

Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA (2009) Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum 52:1359–66PubMedCrossRef

45.

Bufill JA (1990) Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 113:779–88PubMed

46.

Li FY, Lai MD (2009) Colorectal cancer, one entity or three. J Zhejiang Univ Sci B 10:219–29PubMedCrossRef

47.

Nilbert M, Planck M, Fernebro E, Borg A, Johnson A (1999) Microsatellite instability is rare in rectal carcinomas and signifies hereditary cancer. Eur J Cancer 35:942–5PubMedCrossRef

48.

Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P et al (2004) Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 10:4015–21PubMedCrossRef

49.

Horst D, Reu S, Kriegl L, Engel J, Kirchner T, Jung A (2009) The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. Cancer 115:2063–70PubMedCrossRef

50.

Mulcahy MF, Benson AB 3rd (1999) The role of carcinoembryonic antigen monitoring in management of colorectal cancer. Curr Oncol Rep 1:168–72PubMedCrossRef

51.

Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM et al (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–78PubMed

52.

Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R et al (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43:1348–60PubMedCrossRef

Title: Prognostic Significance of Wnt-1, β-catenin and E-cadherin Expression in Advanced Colorectal Carcinoma
Authors: Aleksandra Stanczak
Rafal Stec
Lubomir Bodnar
Wojciech Olszewski
Marzena Cichowicz
Wojciech Kozlowski
Cezary Szczylik
Tadeusz Pietrucha
Maciej Wieczorek
Monika Lamparska-Przybysz
Publication date: 01-12-2011
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9409-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Ezrin Expression as a Prognostic Marker in Colorectal Adenocarcinoma

Invasion of the Hypoglossal Nerve by Adenoid Cystic Carcinoma of the Tongue: Case Report and Review of the Literature

Kaposiform Hemangioendothelioma of the Spleen in an Adult: An Initial Case Report

Watchful Waiting and Active Surveillance Approach in Patients with Low Risk Localized Prostatic Cancer: An Experience of Out-Patients Clinic with 12-Year Follow-Up

Roles of Hormones and Signaling Molecules in Describing the Relationship Between Obesity and Colon cancer

Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables

Keynote webinar | Spotlight on antibody–drug conjugates in cancer